glp 1 gip glucagon triple agonist Polyagonists Enable Increasingly Effective Treatment of Obesity and Diabetes | DZD parkinson's disease triple agonist glp-1

Current UK guidance from the MHRA, NICE, and manufacturers' product information consistently advises against using GLP-1 medications during lactation due to insufficient safety data

Targeted medicines with few adverse effects may become a reality once these pathways are understood

Therefore, it might be useful to expand the evidence on high-dose liraglutide, also considering that there are no direct studies that compare high-dose liraglutide and metformin

212 Furthermore, the anti-inflammatory properties of GLP-1 RAs constitute another notable effect

doi: 10.1016/j.molimm.2019.09.021

How their strategy needs to change to capture the opportunity from or mitigate the risk of GLP-1RAs